Skip to content
ClinCalc Pro
Menu
Recombinant C1 esterase inhibitor

Conestat alfa

Brand names: Ruconest

Conestat alfa is a recombinant human C1-esterase inhibitor used to treat acute angioedema attacks in adults and adolescents with hereditary angioedema due to C1-esterase inhibitor deficiency.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is a recombinant form of human C1-esterase inhibitor that replaces the deficient or dysfunctional protein, restoring regulation of the complement and contact (kallikrein-kinin) systems and reducing bradykinin-mediated swelling.

Prescribing in practice

  • It is produced in the milk of transgenic rabbits and is contraindicated in patients with known or suspected allergy to rabbits or rabbit-derived products.
  • It is administered by slow intravenous injection for the treatment of acute attacks.
  • Hypersensitivity reactions can occur and may be difficult to distinguish from angioedema, so it should be given where appropriate management is available, per the SPC.

Monitoring

Monitor for resolution of the acute attack and for signs of hypersensitivity during and after administration.

Counselling the patient

  • This medicine treats sudden swelling attacks of hereditary angioedema.
  • Tell your clinician if you are allergic to rabbits, as it is derived from rabbit milk.
  • Seek urgent help if you develop signs of an allergic reaction such as rash, wheeze or worsening swelling.

Evidence & guidelines

Conestat alfa is supported by randomised controlled trials demonstrating reduced time to relief of acute hereditary angioedema attacks.

Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.